Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06330870 Recruiting - Breast Cancer Clinical Trials

Brain Metastasis Development Mechanism in BCBM Patients

Start date: April 6, 2023
Phase: N/A
Study type: Interventional

This study is the experimental study for brain metastasis development mechanism in patients with breast cancer with brain metastasis

NCT ID: NCT06330012 Recruiting - Clinical trials for HER2-positive Breast Cancer

The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

Start date: March 18, 2024
Phase: N/A
Study type: Interventional

This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.

NCT ID: NCT06329089 Recruiting - Clinical trials for Recurrent Breast Cancer

Reoperative Sentinel Lymph Node Biopsy in Patients With Recurrent Ipsilateral Breast Cancer

RENATA
Start date: January 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to assess the effectiveness of sentinel lymph node biopsy as a treatment approach for patients with recurrent breast cancer on the same side as previous surgeries. The main questions it aims to answer are: - What is the rate of identification of the sentinel lymph node, and how does it vary among patients with different histories of axillary surgeries? - How can we describe and understand the drainage pathways, including those from the armpit on the same side as the cancer, the area near the breastbone, and the opposite armpit? Participants will undergo sentinel lymph node biopsy as part of their treatment for recurrent breast cancer. They will also receive standard treatments, including surgery and adjuvant therapies as recommended by their healthcare team.

NCT ID: NCT06328738 Recruiting - Colorectal Cancer Clinical Trials

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in participants with advanced-stage HER2-positive colorectal cancer and breast cancer.

NCT ID: NCT06328465 Recruiting - Clinical trials for Triple Negative Breast Cancer

fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases

fREEDOM
Start date: November 22, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to understand whether DWB-MRI (Diffusion Whole Body-Magnetic Resonance Imaging) is useful for early detection of locoregional or distant recurrence and whether early diagnosis influences the prognosis in high-risk populations thanks to the possibility of being able to use a more effective treatment. The primary objective is to evaluate 5-year overall survival (OS) in patients with Human Epidermal Growth Factor Receptor 2 positive (HER2+) or high-risk Triple Negative (TN) undergoing surveillance with DWB-MRI.

NCT ID: NCT06328387 Recruiting - Clinical trials for Metastatic Breast Cancer

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Start date: January 29, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Advanced breast cancer is a special subtype of human breast cancer. Conventional guidelines recommend chemotherapy combined with other adjuvant therapies for this subtype of patients. However, the choice of treatment for these patients after treatment progress is a research hotspot in this field. Trastuzumab Deruxtecan (T-DXd) and Sacituzumab Govitecan (SG) are new ADC drugs targeting HER2 or TROP-2 with high efficacy and low toxicity after the progress of first-line treatment. The autophagy agents hydroxychloroquine or chloroquine has become the only FDA (Food and Drug Administration) approved autophagy inhibitor, and hydroxychloroquine and antibody-drug conjugate(ADC) may have synergistic effects based on the previous work results of our research group. Therefore,we envisage that Trastuzumab Deruxtecan(T-DXd) or Sacituzumab Govitecan (SG) combined with hydroxychloroquine(HCQ) in the treatment of advanced breast cancer in clinical practice has the advantages of improving efficacy and survival. To this end, we intend to conduct a prospective,multi-center, phase I/II clinical trial to evaluate the efficacy and safety of T-DXd or SG in combination with HCQ in patients with advacned breast cancer.

NCT ID: NCT06327607 Recruiting - Breast Cancer Clinical Trials

Psychosexuological Interventions to Support Sexual Function in Breast Cancer Patients

Start date: June 9, 2023
Phase:
Study type: Observational

Prospective pilot study on the feasibility and efficacy of a brief psychosexual support intervention in breast cancer patients undergoing hormonal therapies for at least 6 months. The study is randomized in the two following arms: Control arm (standard care pathway) Psychosexual intervention arm

NCT ID: NCT06327438 Recruiting - Breast Neoplasms Clinical Trials

Effect of Complex Decongestive Therapy, Cryotherapy and Kinesio Taping in Patients With Post-mastectomy Lymphedema: A Randomized Control Trial

Start date: March 16, 2024
Phase: N/A
Study type: Interventional

To examine the efficacy of complex decongestive therapy (CDT), cryotherapy and kinesio taping (KT) in patients with post-mastectomy lymphedema

NCT ID: NCT06321653 Recruiting - Breast Cancer Clinical Trials

Lymphedema Evaluation After Adjuvant Hypofractionated Radiotherapy for 1-2 Macrometastatic Sentinel Lymph Nodes

AXILL-ART
Start date: April 18, 2019
Phase:
Study type: Observational

In this observational prospective studi patients with invasive breast cancer no more than 5 cm and clinically node negative, scheduled for conservative surgery and Sentinel Node Biopsy (SNB), are enrolled in the protocol if they have 1-2 sentinel lymphnodes (SLNs) with macrometastases. SLN status will be checked on definitive sections.

NCT ID: NCT06319157 Recruiting - Breast Neoplasms Clinical Trials

Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction

Start date: March 2024
Phase: N/A
Study type: Interventional

For patients refusing implants for breast reconstruction after cancer surgery, autologous tissue flap reconstruction using the latissimus dorsi muscle is an alternative. Conventional surgery leaves a long incision on the back, affecting aesthetics and quality of life. Minimal access techniques result in a smaller, more concealable scar. While previous studies suggest its safety and effectiveness, most are retrospective. To further validate patient satisfaction and short-term outcomes, a prospective, randomized controlled trial comparing minimal access with conventional surgery is planned. The primary endpoint is Breast Q-satisfaction with back score at 6 months. Secondary outcomes include other Breast Q subscales, surgical metrics, and complications. The study aims to enroll 94 patients in total, providing evidence for surgical decision-making in breast cancer reconstruction.